EUVIMEDEUVIMED entdecken
Crossref

Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinoma

Minh T Than iD, Lucie Dequiedt iD, Rina Sor iD, Shreya Nair, Nune Markosyan, Emma E Furth iD, Chenghua Yang iD, Courtney Ray-Fofana, Marie Menard, Elsa Quintana, A Cole Edwards, Connor J Hennessey iD und 7 weitere

Science · 12.03.2026 · 391 (6790) · 1161-1166

DOI: 10.1126/science.aec7929 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science, erschienen am 12.03.2026. Verfasst von Minh T Than und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Precancerous Conditions. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: NCI NIH HHS, National Institutes of Health, U.S. Department of Defense.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Transformation of pancreatic epithelial cells to malignant pancreatic ductal adenocarcinoma (PDAC) typically involves the progression of precancerous pancreatic intraepithelial neoplasia (PanINs) bearing oncogenic KRAS mutations. Here, we tested the impact of PDAC interception using either RAS(ON) multiselective or RAS(ON) G12D-selective pharmacological inhibitors [RAS(ON) inhibitors] in mouse models of PDAC. Treatment of PanIN-bearing mice with RAS(ON) inhibitors prompted regression of premalignant lesions that translated into a delay in tumor onset and an increase in overall survival (OS). Long-term interception in tumor-prone mice resulted in a median OS of more than 1 year compared with less than 5 months in nonintercepted control mice ( P < 0.0001). Comparing the survival benefits of RAS(ON) inhibition for cancer interception versus RAS(ON) inhibition for cancer treatment, we found that interception provided a greater survival benefit to mice. These findings suggest that a pharmacological approach may reduce premalignant burden and increase survival in PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsCarcinoma, Pancreatic DuctalPancreatic NeoplasmsPrecancerous ConditionsProto-Oncogene Proteins p21(ras)AnimalsHumansMiceDisease Models, AnimalMutation

Substanzen

Antineoplastic AgentsKras protein, mouseProto-Oncogene Proteins p21(ras)

Autor:innen und Institutionen

  • Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
  • Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA.
  • Department of Pathology, University of Pennsylvania, Philadelphia, PA, USA.
  • Revolution Medicines, Redwood City, CA, USA.
  • Sol Goldman Pancreatic Cancer Research Center, Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA.

ORCID-Profile: Minh T Than, Lucie Dequiedt, Rina Sor, Emma E Furth, Chenghua Yang, Connor J Hennessey, Austin L Good, Liz Quinones, Cynthia Clendenin, Ashley L Kiemen, Robert H Vonderheide, Ben Z Stanger

Förderung

  • NCI NIH HHS
  • National Institutes of Health
  • U.S. Department of Defense
  • Conquer Cancer Foundation
  • Lustgarten Foundation
  • Rolfe Pancreatic Cancer Foundation
  • Basser Center for BRCA
  • Sponsored Research Award Revolution Medicines RHV BZS

Zitieren

APA

Than, M. T., Dequiedt, L., Sor, R., Nair, S., Markosyan, N., Furth, E. E., Yang, C., Ray-Fofana, C., Menard, M., Quintana, E., Edwards, A. C., Hennessey, C. J., Good, A. L., Quinones, L., Hwang, Y., Clendenin, C., Kiemen, A. L., Vonderheide, R. H., & Stanger, B. Z. (2026). Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinoma. Science, 391(6790), 1161-1166. https://doi.org/10.1126/science.aec7929

Vancouver

Than MT, Dequiedt L, Sor R, Nair S, Markosyan N, Furth EE, et al. Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinoma. Science. 2026;391(6790):1161-1166. doi:10.1126/science.aec7929

BibTeX
@article{Than2026,
  author = {Than, Minh T and Dequiedt, Lucie and Sor, Rina and Nair, Shreya and Markosyan, Nune and Furth, Emma E and Yang, Chenghua and Ray-Fofana, Courtney and Menard, Marie and Quintana, Elsa and Edwards, A Cole and Hennessey, Connor J and Good, Austin L and Quinones, Liz and Hwang, Yunseo and Clendenin, Cynthia and Kiemen, Ashley L and Vonderheide, Robert H and Stanger, Ben Z},
  title = {Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinoma},
  journal = {Science},
  year = {2026},
  volume = {391},
  number = {6790},
  pages = {1161--1166},
  doi = {10.1126/science.aec7929}
}
Kostenlos starten →